Pharmaceutical Research

, Volume 20, Issue 3, pp 417–422 | Cite as

Antitumor Activity of Folate Receptor-Targeted Liposomal Doxorubicin in a KB Oral Carcinoma Murine Xenograft Model



Purpose. The expression of folate receptor (FR) is amplified in many types of human cancers. Previously, FR-targeted liposomal doxorubicin (f-L-DOX) has been shown to exhibit superior and selective cytotoxicity against FR(+) tumor cells in vitro compared to nontargeted liposomal doxorubicin (L-DOX). This study further investigates f-L-DOX for its antitumor efficacy in vivo using a murine tumor xenograft model.

Methods. F-L-DOX composed of DSPC/cholesterol/PEG-DSPE/folate-PEG-DSPE (65:31:3.5:0.5, mole/mole) was prepared by polycarbonate membrane extrusion followed by remote loading of DOX. Athymic mice on a folate-free diet were engrafted with FR(+) KB cells. Two weeks later, these mice were treated with f-L-DOX, L-DOX, or free DOX in a series of six injections (given intraperitoneally on every fourth day at 10 mg/kg DOX) and monitored for tumor growth and animal survival. The plasma clearance profiles of the DOX formulations and the effect of dietary folate on plasma folate concentration were also analyzed.

Results. Plasma folate level remained in the physiologic range relative to that in humans. F-L-DOX exhibited an extended systemic circulation time similar to that of L-DOX. Mice that received f-L-DOX showed greater tumor growth inhibition and a 31% higher (p < 0.01) increase in lifespan compared to those that received L-DOX. Meanwhile, free DOX given at the same dose resulted in significant toxicity and was less effective in prolonging animal survival.

Conclusions. FR-targeted liposomes are a highly efficacious vehicle for in vivo delivery of anticancer agents and have potential application in the treatment of FR(+) solid tumors.

folate receptor drug targeting liposomes doxorubicin xenograft 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    D. Goren, A. T. Horowitz, D. Tzemack, M. Tarshish, S. Zalipsky, and A. Gabizon. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 6:1949-1957 (2000).Google Scholar
  2. 2.
    P. Garin-Chesa, I. Campbell, P. E. Saigo, J. L. Lewis Jr., L. J. Old, and W. J. Rettig. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am. J. Pathol. 142:557-567 (1993).Google Scholar
  3. 3.
    J. F. Ross, P. K. Chaudhuri, and M. Ratnam. Differential #x00AEulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines—Physiologic and clinical implications. Cancer 73:2432-2443 (1994).Google Scholar
  4. 4.
    J. F. Ross, H. Wang, F. G. Behm, P. Mathew, M. Wu, R. Booth, and M. Ratnam. Folate receptor type Β is neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 85:348-357 (1999).Google Scholar
  5. 5.
    J. J. Sudimack and R. J. Lee. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 41:147-162 (2000).Google Scholar
  6. 6.
    J. A. Reddy and P. S. Low. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit. Rev. Ther. Drug Carrier Syst. 15:587-627 (1998).Google Scholar
  7. 7.
    R. J. Lee and P. S. Low. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 269:3198-3204 (1994).Google Scholar
  8. 8.
    W. Guo, T. Lee, J. J. Sudimack, and R. J. Lee. Receptor-specific delivery of liposomes via folate-PEG-chol. J. Liposome Res. 10:179-195 (2000).Google Scholar
  9. 9.
    A. Gabizon. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 19:424-436 (2001).Google Scholar
  10. 10.
    R. J. Lee and P. S. Low. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Bio#x03A7;m. Biophys. Acta 1233:134-144 (1995).Google Scholar
  11. 11.
    A. Gabizon, A. T. Horowitz, D. Goren, D. Tzemach, F. Madelbaum-Shavit, M. M. Qazen, and S. Zalipsky. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug. Chem. 10:289-298 (1999).Google Scholar
  12. 12.
    X. Q. Pan, X. Zheng, G. Shi, H. Wang, M. Ratnam, and R. J. Lee. Strategy for the treatment of acute myelogenous leukemia based on folate receptor Β-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 100:594-602 (2002).Google Scholar
  13. 13.
    X. Q. Pan, H. Wang, and R. J. Lee. Boron delivery to a murine lung carcinoma using folate receptor-targeted liposomes. Anticancer Res. 22:1629-1634 (2002).Google Scholar
  14. 14.
    M. J. Turk, D. J. Waters, G. Breur, W. R. Widmer, and P. S. Low. Folate-mediated targeting of liposomes to tumor cells and Mac-1 expressing cells in vivo. J. Control. Release 74:369-376 (2001).Google Scholar
  15. 15.
    J. C. Stewart. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 104:10-14 (1980).Google Scholar
  16. 16.
    W. Guo, G. H. Hinkle, and R. J. Lee. 99mTc-HYNIC-folate, a novel receptor-based targeted radiopharmaceutical for tumor imaging. J. Nucl. Med. 40:1563-1569 (1999).Google Scholar
  17. 17.
    J. Plowman, D. J. Dykes, M. Hollingshead, L. Simpson-Herren, and M. C. Alley. Human tumor xenograft models in NCI drug development. In B. Teicher (ed.), Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Humana Press, Totowa, New Jersey, 1997, pp. 101-125.Google Scholar
  18. 18.
    R. L. Hong, C. J. Huang, Y. L. Tseng, V. F. Pang, S. T. Chen, J. J. Liu, and F. H. Chang. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin. Cancer Res. 5:3645-3652 (1999).Google Scholar
  19. 19.
    J. Song, A. Medline, J. B. Mason, S. Gallinger, and Y.-I. Kim. Effects of dietary folate on intestinal tumorigenesis in the Apc Min mouse. Cancer Res. 60:5424-5440 (2000).Google Scholar
  20. 20.
    R. F. Branda, E. Nigels, A. R. Lafayette, and M. Hacker. Nutritional folate status influences the efficacy and toxicity of chemotherapy in rats. Blood 92:2471-2476 (1998).Google Scholar
  21. 21.
    J. M. Lawrence, D. B. Petitti, M. Watkins, and M. A. Umekubo. Trends in serum folate after food fortification. Lancet 354:915-916 (1999).Google Scholar
  22. 22.
    R. L. Walzem and A. J. Clifford. Folate deficiency in rats fed diets containing free amino acids or intact proteins. J. Nutr. 118:1089-1096 (1988).Google Scholar
  23. 23.
    R. K. Jain. Delivery of molecular medicine to solid tumors:lessons from in vivo imaging of gene expression and function. J. Control. Release 73:7-25 (2001).Google Scholar
  24. 24.
    J. W. Park, K. Hong, D. B. Kirpotin, D. Papahadjopoulos, and C. C. Benz. Immunoliposomes for cancer treatment. Adv. Pharmacol. 40:399-435 (1997).Google Scholar
  25. 25.
    T. Shinoda, A. Takagi, A. Maeda, S. Kagatani, Y. Konno, and M. Hashida. In vivo fate of folate-BSA in non-tumor-and tumor-bearing mice. J. Pharm. Sci. 87:1521-1526 (1998).Google Scholar
  26. 26.
    J. L.-S. Au, S. H. Jang, and M. G. Wientjes. Clinical aspects of drug delivery to tumors. J. Control. Release 78:81-95 (2002).Google Scholar

Copyright information

© Plenum Publishing Corporation 2003

Authors and Affiliations

  1. 1.Division of Pharmaceutics, College of PharmacyThe Ohio State UniversityColumbus

Personalised recommendations